4-Butyl-cyclohexanecarboxylic acid 4'-cyano-biphenyl-4-yl ester | 67284-58-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Butyl-cyclohexanecarboxylic acid 4'-cyano-biphenyl-4-yl ester
• 英文别名: 4-(4-Cyanophenyl)phenyl 4-butylcyclohexane-1-carboxylate；[4-(4-cyanophenyl)phenyl] 4-butylcyclohexane-1-carboxylate
• CAS: 67284-58-6
• 化学式: C₂₄H₂₇NO₂
• mdl: MFCD00689065
• 分子量: 361.484
• InChiKey: UPZWPROWEKXOLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• CHIRAL COMPOUNDS, CHOLESTERIC AND FERROELECTRIC LIQUID CRYSTAL COMPOSITIONS COMPRISING THESE CHIRAL COMPOUNDS, AND LIQUID CRYSTAL DISPLAYS COMPRISING THESE LIQUID CRYSTAL COMPOSITIONS
  申请人：Haase Wolfgang

  公开号：US20110233463A1

  公开（公告）日：2011-09-29

  Chiral liquid crystal compounds of the general formula (1): in which at least one of R 1 and R 2 is a chiral substituent, K may be a single bond or the same as K 1-5 and K 1-5 denote a six-membered ring system which rings may be at least partially unsaturated, wherein the number of atoms in these rings or ring systems between the two atoms forming a part of the link to the next ring, or to one of the substituents R 1 and R 2 , does not differ by more than one if counted in the clockwise, and in the counter-clockwise sense, starting from the same atom in each case, X 1-20 denote alkyl, or alkoxy, or fluorinated alkyl, or fluorinated alkoxy groups, or atom H, or halogen atoms, mixtures comprising such chiral liquid crystal compounds, and liquid crystal displays comprising such mixtures as active ingredients

  手性液晶化合物的一般式（1）： 其中至少一个R1和R2是手性取代基，K可以是单键或与K1-5相同，K1-5表示一个六元环系统，这些环可能至少部分不饱和，在这些环或环系统中，两个形成连接到下一个环或取代基R1和R2之一的原子之间的原子数，在顺时针和逆时针方向上计数时，从同一原子开始，在每种情况下不超过一，X1-20表示烷基、或烷氧基、或氟代烷基、或氟代烷氧基、或原子H、或卤素原子，以及包含这种手性液晶化合物的混合物，以及包含这种混合物作为活性成分的液晶显示器。
• LIQUID-CRYSTAL MEDIUM
  申请人：Merck Patent GmbH

  公开号：EP3502210A1

  公开（公告）日：2019-06-26

  The present invention relates to an LC medium comprising and a liquid-crystalline host consisting of an LC component H) comprising one or more mesogenic or liquid-crystalline compounds and an optically active component D) and optionally a polymerisable component P) comprising one or more polymerisable compounds; and to the use of the polymerisable compounds and LC media for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the polymer sustained alignment type.

  本发明涉及一种液晶介质，该介质包括由一种或多种介晶或液晶化合物组成的液晶成分 H) 和光学活性成分 D)，以及由一种或多种可聚合化合物组成的可聚合成分 P)；本发明还涉及将可聚合化合物和液晶介质用于光学、电子光学和电子用途，特别是用于液晶显示器，尤其是用于聚合物持续排列类型的液晶显示器。
• LIQUID CRYSTAL MEDIUM
  申请人：Merck Patent GmbH

  公开号：EP3839008A1

  公开（公告）日：2021-06-23

  The present invention relates to a liquid crystal (LC) medium comprising a compound of formula I and one or more compounds selected from the group of compounds of the formulae IIA, IIB, IIC and IID, as defined in claim 1, and to the use of the LC medium for optical, electro-optical and electronic purposes, in particular in LC displays, especially in IPS, FFS, VA or PS-VA displays.

  本发明涉及一种液晶（LC）介质，该介质由式 I 的化合物组成 和 一种或多种选自式 IIA、IIB、IIC 和 IID 化合物组的化合物、 如权利要求 1 所定义，将 LC 介质用于光学、电子光学和电子用途，特别是用于 LC 显示器，尤其是 IPS、FFS、VA 或 PS-VA 显示器。
• Cell migration inhibiting compositions and methods and compositions for treating cancer
  申请人：Edwards L. David

  公开号：US20060128742A1

  公开（公告）日：2006-06-15

  Methods for treating an individual having cancer are provided. The method may include administering a cell migration inhibitor and a chemotherapeutic agent to the individual to inhibit migration of cancer cell. Inhibiting cell migration may increase cell division. In this manner, the cell migration inhibitor and the chemotherapeutic agent in combination may have increased efficacy compared to the chemotherapeutic agent alone due to the increased cell division. The cell migration inhibitor may include any of the inhibitors described herein. For example, the cell migration inhibitor may be an organic molecule having a molecular weight of less than about 700, a monoclonal antibody, or a natural product.

  本文提供了治疗癌症患者的方法。该方法可包括向患者施用细胞迁移抑制剂和化疗药物，以抑制癌细胞的迁移。抑制细胞迁移可增加细胞分裂。这样，由于细胞分裂增加，细胞迁移抑制剂和化疗剂联合使用的疗效可能比单独使用化疗剂的疗效更好。细胞迁移抑制剂可包括本文所述的任何抑制剂。例如，细胞迁移抑制剂可以是分子量小于约 700 的有机分子、单克隆抗体或天然产物。
• CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER
  申请人：Avolix Pharmaceuticals

  公开号：EP1576110A2

  公开（公告）日：2005-09-21